There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Astria Therapeutics (ATXS – Research Report) and Aslan Pharmaceuticals (ASLN – Research Report) with bullish sentiments.
Legend Biotech (LEGN)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech today and set a price target of $87.00. The company’s shares closed last Monday at $47.06, close to its 52-week low of $45.52.
According to TipRanks.com, Kapoor has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $86.58 average price target, representing an 86.7% upside. In a report issued on April 17, Scotiabank also upgraded the stock to Buy with a $65.00 price target.
See the top stocks recommended by analysts >>
Astria Therapeutics (ATXS)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Astria Therapeutics, with a price target of $16.00. The company’s shares closed last Monday at $9.80.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of
Astria Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.67.
Aslan Pharmaceuticals (ASLN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Aslan Pharmaceuticals today and set a price target of $9.00. The company’s shares closed last Monday at $0.46, close to its 52-week low of $0.39.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals with a $9.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
- European Approval for Legend Biotech’s Myeloma Treatment
- Scotiabank upgrades Legend Biotech on attractive entry point
- Legend Biotech upgraded to Outperform from Sector Perform at Scotiabank
- J&J report ‘not alarming’ for Legend Biotech, says H.C. Wainwright
- Legend Biotech Reports Preliminary Sales Surge
